Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Impel Pharmaceuticals Inc. IMPL

Impel Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. The company is developing an approach to drug delivery that administers specific formulations of drugs deep into the vascular-rich upper nasal space, a gateway for therapeutic administration of a versatile range of molecules and formulations.


Recent & Breaking News (NDAQ:IMPL)

Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in September

GlobeNewswire September 6, 2022

Impel Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire August 15, 2022

Impel Pharmaceuticals to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022

GlobeNewswire August 8, 2022

Impel Pharmaceuticals to Participate in 2022 Wedbush PacGrow Healthcare Conference

GlobeNewswire August 2, 2022

Impel Pharmaceuticals Announces First Patient Dosed in Phase 2a Study Evaluating INP105 to Treat Acute Agitation in Adolescents With Autism Spectrum Disorder (ASD)

GlobeNewswire July 19, 2022

Impel Pharmaceuticals to Present Trudhesa® Data at the 64th Annual Meeting of the American Headache Society

GlobeNewswire June 9, 2022

Impel Pharmaceuticals To Present At The JMP Securities Life Sciences Conference

GlobeNewswire June 8, 2022

Impel Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire May 16, 2022

Impel Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

GlobeNewswire May 12, 2022

Impel Pharmaceuticals to Report First Quarter 2022 Financial Results on Monday, May 16, 2022

GlobeNewswire May 9, 2022

Impel Neuropharma Announces Company Will Now Be Known as Impel Pharmaceuticals to Reflect Corporate Transformation

GlobeNewswire April 25, 2022

Impel NeuroPharma to Ring Nasdaq Closing Bell on Monday, April 25

GlobeNewswire April 21, 2022

Impel NeuroPharma To Present At The 21st Annual Needham Healthcare Conference

GlobeNewswire April 7, 2022

Impel NeuroPharma Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

GlobeNewswire March 24, 2022

Impel NeuroPharma to Present Trudhesa(TM) Data at 2022 Scientific Meeting of American Academy of Neurology

GlobeNewswire March 22, 2022

Impel NeuroPharma to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022

GlobeNewswire March 17, 2022

Impel Neuropharma Announces $100 Million Royalty and Debt Financing Agreement With Oaktree

GlobeNewswire March 17, 2022

Impel NeuroPharma to Participate in Upcoming Virtual Investor Conferences

GlobeNewswire February 28, 2022

Impel NeuroPharma Provides Updates on Trudhesa(TM) Launch and Recent Business Highlights

GlobeNewswire January 18, 2022

Impel NeuroPharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire November 15, 2021